Executive Summary
For induced pluripotent stem cell (iPSC) and other somatic cell therapy programs, the quality of the starting plasmid DNA is a foundational determinant of downstream success. The plasmid functions as a foundational raw material that dictates the integrity of gene editing, the stability of differentiation protocols, and the safety profile of the final therapeutic product. We produce high-purity, low-endotoxin plasmid DNA suitable for the demanding requirements of iPSC reprogramming, CRISPR-based gene editing, and the generation of master cell banks under a GxP framework. Our approach integrates principles from advanced vectorology to mitigate risks associated with immunogenicity and off-target effects, accelerating the path to a successful IND submission.
Frequently Asked Questions
Q: How does plasmid DNA quality impact IND-enabling studies for iPSC-derived therapies?
Plasmid DNA quality directly influences the consistency and safety profile of the final cell product. High-purity plasmids with verified topology and low endotoxin levels minimize the risk of unintended cellular responses, poor editing efficiency, or instability in differentiated cells. Documenting these quality attributes forms a core component of the CMC section for an IND submission.
Q: What are the key analytical considerations for plasmids used in GxP-compliant cell therapy manufacturing?
Key analytical release criteria include identity (restriction digest, sequencing), purity (A260/A280, HPLC), and safety (endotoxin, bioburden). The percentage of supercoiled plasmid is also a key quality attribute, as it correlates with higher transfection efficiency and more consistent performance in iPSC and stem cell engineering protocols.
Q: Can you support plasmid production for both nuclease platforms like CRISPR-Cas9 and newer precision editors?
Yes. We provide plasmid DNA services for a range of gene editing systems. This includes constructs for delivering standard nuclease platforms like CRISPR-Cas9 as well as more advanced base editors and prime editors, which require precise vector design to ensure the fidelity of the editing machinery.
Foundational Integrity for Cellular Engineering
The success of next-generation therapeutics derived from iPSCs and other stem cells depends on the precise and reproducible manipulation of their genetic code. The plasmid DNA used to deliver reprogramming factors or gene editing components is a foundational raw material that influences the entire manufacturing cascade. Inconsistent plasmid quality can introduce variability that compromises master cell bank integrity and complicates regulatory filings.
Our plasmid production services are specifically designed to support the unique demands of somatic cell therapy programs. We focus on delivering material with high supercoiled content and minimal endotoxin contamination, attributes that are directly linked to higher efficiency and reduced cytotoxicity in sensitive pluripotent cell cultures.
Strategic Plasmid Design Informed by Vector Biology
A data-driven preclinical strategy requires understanding how vector components influence biological outcomes. Insights from in vivo vector systems provide valuable principles for designing plasmids intended for cellular engineering.
-
Controlling Expression and Immunogenicity: The selection of promoter and other regulatory elements is a known strategy for controlling transgene expression and mitigating unwanted immune responses. This principle, validated in viral vector systems (PMID: 14759807), directly informs our plasmid design philosophy for generating stable and predictable iPSC lines for therapeutic use.
-
Minimizing Innate Immune Activation: Vector backbones themselves can trigger immune activation, a finding observed in nonhuman primate models (PMID: 24829340). For cellular therapy programs, this reinforces the requirement for exceptionally pure plasmid DNA to prevent unintended differentiation or activation of sensitive stem cell cultures, ensuring the final product is defined only by its intended modifications.
Our approach provides the analytical foundation required to accelerate programs toward IND, typically within an 18-24 month timeline. This track record is built on the deep experience of our core scientific team, whose work has contributed to a 100% successful IND rate since 2019, prior to the formal launch of Franklin Biolabs in 2024. All work is conducted within our >100,000 sq ft facilities.
These services are a component of our broader capabilities in vector production and analytics. For a complete overview, please see our main services page.
Vector | CMC | Analytics Services
Featured Video: Franklin BioLab Facility Tour
This site tour showcases Franklin Biolabs’ preclinical and bioanalytical facilities, spanning >100k sq ft of animal housing and specialized laboratory space.
Watch Video Clip
